Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect?Zacks Investment Research • 01/10/24
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 12/12/23
89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 12/07/23
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 12/06/23
89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024GlobeNewsWire • 12/04/23
89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)GlobeNewsWire • 11/27/23
89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023GlobeNewsWire • 11/12/23
89bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/08/23
89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor ConferenceGlobeNewsWire • 10/17/23
Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bioInvestors Business Daily • 10/10/23
89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)GlobeNewsWire • 09/21/23
89bio to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
89bio earns ‘Buy' rating in initial coverage on positive prospects for NASH therapeuticProactive Investors • 08/28/23
89bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/09/23
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature MedicineGlobeNewsWire • 06/24/23
Data from 89bio's ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver CongressGlobeNewsWire • 06/24/23